Molecular imaging is poised to make greater inroads into clinical practice in the next decade. Clinical evidence supporting broader use of PET/CT continues to mount, and the U.S. Centers for Medicare and Medicaid Services (CMS) recently issued a national coverage decision expanding Medicare reimbursement to 11 cancers.

How do you acquire the high–field-strength open MRI unit of your dreams in a tough economy? Unless you had already budgeted a cool million before the economy tanked, it may be difficult. David Nelson, director of outpatient imaging for BayCare Health System, Clearwater, Fla, overcame his lack of comfort with open systems last year and did just that

The design and subsequent implementation of NOPR followed a novel concept (coverage with evidence development) that mandates the development of evidence prior to CMS (Centers for Medicare & Medicaid Services) reimbursement for services.

Molecular Imaging Insight visits pioneers across the country to determine how molecular imaging is improving detection, risk stratification and treatment of coronary artery disease.

As researchers continue to explore the role of stem cell therapy in cardiac medicine, molecular imaging will take center stage. Thats because transplanted cells must be tracked and monitored in vivo. Here is a closer look at various clinical trials focused on the potential of cardiac stem cell therapies that offer a better understanding of how various molecular imaging modalities will contribute to and measure the eventual clinical utility of cardiac stem cell-based therapies.

In an era that is becoming more focused on the need for developing evidence-based and personalized medicine, molecular imaging provides a detailed look into human physiology and disease at the cellular and molecular level.

Molecular Imaging Insight spoke with three experts to discuss the evidence supporting a coverage expansion, reaction to CMS proposed decision memo and speculate on what the final verdict might be.

In February, France's state-operated agency for the funding of innovation awarded a research-and-development grant worth 8.5 million euros to a European company that wants to validate a new application clinically for the still-nascent modality of ultrasound elastography. In this instance, elastography would be used as a targeting mechanism for the